Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (4031)	6/6/2001 11:44:29 AM
From: Biomaven	Read Replies (2) \| Respond to of 52153

<<Pravachol/Niaspan>> Is that something that they could get approval for? Undoubtedly. No reason to expect that it wouldn't just be a better version of the drug KOSP is now developing. Could be a very big seller with the BMY marketing muscle behind it. Interesting idea, but it would need some fast thinking and movement here by BMY to satisfy KOSP (and perhaps the FCC). I still think it's more likely that KOSP will just be cut loose with a significant payment to keep them happy. Peter